Adoptive immunotherapy with double‐bright (CD56 bright /CD16 bright ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof‐of‐concept study-Reference-Cited by-同舟云学术

Adoptive immunotherapy with double‐bright (CD56 bright /CD16 bright ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof‐of‐concept study

Published:2021-09-07 Issue:5 Volume:195 Page:710-721
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Silla Lucia¹²^ORCID,Valim Vanessa²,Pezzi Annelise²^ORCID,Silva Maria²,Wilke Ianae¹,Nobrega Juliana²,Vargas Alini²,Amorin Bruna²,Correa Bruna¹,Zambonato Bruna²,Scherer Fernanda²,Merzoni Joice²,Sekine Leo¹²,Huls Helen³,Cooper Laurence J.³,Paz Alessandra²,Lee Dean A.⁴^ORCID

Affiliation:

1. Universidade Federal do Rio Grande do Sul Porto Alegre RSBrazil

2. Hospital de Clínicas de Porto Alegre Porto Alegre RS Brazil

3. University of Texas MD Anderson Cancer Center Houston TXUSA

4. Nationwide Children’s Hospital Columbus OH USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17751

Reference35 articles.

1. SurveillanceINCEpidemiology and End Results (SEER) stat facts: leukemia‐acute myeloid leukemiahttps://seer.cancer.gov/statfacts/html/amyl.html:Accessed August 2020; 2018.

2. Relapsed acute myeloid leukemia: Why is there no standard of care?

3. Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia

4. Midostaurin in FLT3‐mutated acute myeloid leukemia;Stone RM;N Engl J Med,2017

5. Single-agent and combination biologics in acute myeloid leukemia

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological effects of IL-21 on immune cells and its potential for cancer treatment;International Immunopharmacology;2024-01

2. Editorial: 50 years of BMT: risk stratification, donor matching and stem cell collection for transplantation;Frontiers in Oncology;2023-12-19

3. Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies;Journal for ImmunoTherapy of Cancer;2023-12

4. Improved Leukemia Clearance After Adoptive Transfer of NK Cells Expressing the Bone Marrow Homing Receptor CXCR4R334X;HemaSphere;2023-11

5. Development of Genetically Engineered Feeder Cells for Natural Killer Cell Expansion;Anticancer Research;2023-08-30